IVBXF — Innovent Biologics Inc/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 1774163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 37,347,839,000 | 17,344,705,000 | 17,991,596,000 |
| Jun 2025 | — | — | — | — | 23,594,272,000 | 9,540,139,000 | 9,172,452,000 |
| Dec 2024 | — | — | — | — | 21,602,602,000 | 7,508,185,000 | 8,484,873,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-15,092,803,000
Inventory
$1,301,745,000
Receivables
—
ST Investments
$886,741,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,041,522,688
EBITDA
$1,310,151,936
Free Cash Flow
$3,228,137,984
Enterprise Value
$2,520,335,616
Total Cash
$18,231,445,504
Total Debt
$2,815,774,976
Shares Out
1,734,623,465
Trailing EPS
$0.07
Book Value
$1.64
ROE
5.0%
ROA
1.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,041,523,000 | 2,140,913,000 | 813,565,000 | 37,347,839,000 | 17,991,596,000 | — | 10,001,012,000 |
| Dec 2024 | 9,421,888,000 | 258,119,000 | -94,631,000 | 21,602,602,000 | 8,484,873,000 | — | 1,287,024,000 |
| Dec 2023 | 6,206,070,000 | -909,210,000 | -1,027,913,000 | 20,627,360,000 | 8,099,779,000 | — | 147,810,000 |
| Dec 2022 | 4,556,380,000 | -2,581,885,000 | -2,179,270,000 | 17,588,845,000 | 6,858,896,000 | — | -1,918,804,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRUST | $688.88B | $750.59 | — |
| KLAC | KLA CORP | $262.74B | $2011.39 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $235.62B | $250.69 | — |
| KXIAY | Kioxia Holdings Corporation/ADR | $231.81B | $42.45 | — |
| SMEGF | Siemens Energy AG/ADR | $180.38B | $212.00 | — |
News headlines (Yahoo Finance, 1h cache)
Assessing Innovent Biologics (SEHK:1801) Valuation After Strong Long Term Share Price Gains
2026-05-24 22:12 · Yahoo
/C O R R E C T I O N -- Innovent Biologics/
2026-05-22 04:58 · Yahoo
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherap
2026-05-21 23:49 · Yahoo
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Ren
2026-05-21 10:00 · Yahoo
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Ren
2026-05-21 10:00 · Yahoo
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
2026-05-19 00:00 · Yahoo
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
2026-05-13 00:00 · Yahoo
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
2026-05-11 00:00 · Yahoo
3 Asian Stocks Estimated To Be Up To 31.8% Below Intrinsic Value
2026-04-30 22:34 · Yahoo
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
2026-04-22 00:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.